Against the backdrop of rapidly growing demand for weight-loss medications and increasing competition in digital healthcare, Amazon is effectively turning its pharmacy infrastructure into one of the key distribution channels for GLP-1 therapy in the United States. At FinancialMediaGuide, we note that the combination of online pharmacies, pharmacy kiosks, and same-day prescription delivery is creating a new standard in pharmaceutical logistics, where speed is becoming just as important as the medication itself.
Amazon Pharmacy has begun supplying oral weight-loss medications from Eli Lilly, including new forms of GLP-1 therapy that do not require refrigeration. This factor is fundamentally changing the economics of drug distribution, as it reduces dependence on specialized logistics and expands storage options at pickup locations. At FinancialMediaGuide, we believe that the shift toward oral formulations could become a key driver of mass adoption of obesity treatment, especially among patients who previously avoided injectable drugs.
An additional layer of transformation comes from the integration of pharmacy kiosks into Amazon’s One Medical healthcare infrastructure. A patient can undergo consultation, receive a prescription, and pick up the medication within a single medical ecosystem. At FinancialMediaGuide, we note that this model shortens the time gap between diagnosis and treatment, which is especially critical for chronic conditions such as obesity and type 2 diabetes.
The GLP-1 drug market remains one of the most dynamic segments of the global pharmaceutical industry. Drugs from Eli Lilly and Novo Nordisk are already forming a multi-billion-dollar market with a strong growth trajectory. At FinancialMediaGuide, we emphasize that the emergence of oral formulations could expand the target audience by reducing psychological barriers and simplifying usage regimens, directly accelerating therapy adoption rates.
In parallel, Amazon is scaling its logistics network for prescription delivery. Around half of U.S. users already have access to same-day delivery, and by 2026 the company plans to reach up to 4,500 locations. At FinancialMediaGuide, we see this not merely as service expansion but as the formation of a new pharmaceutical retail infrastructure, where delivery time becomes a competitive advantage equivalent to a healthcare performance metric.
Particular attention should be given to integration with the direct-to-consumer model through LillyDirect. This format reduces the number of intermediaries between manufacturer and patient, simplifying supply chains and improving pricing transparency. At FinancialMediaGuide, we believe this strengthens the trend toward pharmaceutical digitization, where technology companies become key operators of access to therapy.
The pricing factor further enhances market growth potential. Eli Lilly’s Foundayo is priced starting at $149 per month for self-pay patients. At the same time, channels through WW International and GoodRx are expanding, increasing affordability for broader population segments. At FinancialMediaGuide, we note that lower treatment costs for obesity could act as a trigger for rapid demand growth in the GLP-1 segment.
Collaboration with Novo Nordisk strengthens Amazon’s multi-vendor model in pharmaceuticals. Pilot kiosks in California already allow patients to receive medications after medical consultation, combining offline healthcare services with digital distribution. At FinancialMediaGuide, we emphasize that this model improves treatment efficiency by reducing the time between prescription and therapy initiation.
Regulatory constraints remain an important limiting factor for scaling. The deployment of pharmacy kiosks and the expansion of prescription drug sales depend on state-level legislation in the United States. At FinancialMediaGuide, we expect that the gradual adaptation of regulatory frameworks to digital healthcare will support accelerated growth of e-pharmacy and broader access to innovative therapies.
It is also worth noting Amazon’s strategy of expanding service accessibility. Despite the One Medical subscription costing $199 per year, access to pharmacy services remains available to non-members as well. At FinancialMediaGuide, we see this as a pragmatic scaling approach aimed at rapidly increasing market share in the digital healthcare segment.
In a broader context, the GLP-1 weight-loss drug market is becoming one of the key growth drivers of the pharmaceutical industry. At FinancialMediaGuide, we note that interest from investors and technology platforms is intensifying competition and accelerating the development of new therapies, including oral solutions.
We at Financial Media Guide forecast that Amazon is likely to secure a position among the key players in the U.S. online pharmacy and prescription delivery market. The main growth drivers will be the expansion of telemedicine, the scale of its logistics network, and rising demand for weight-loss medications. Key risks include regulatory barriers, competition from traditional pharmacies, and pricing pressure. Nevertheless, the company’s current strategy reflects the formation of a new pharmaceutical market architecture, where logistics, digital services, and pharmaceuticals converge into a unified ecosystem.
